Clicky

Crinetics Pharmaceuticals Inc(6Z4)

Description: Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.


Keywords: Pharmaceutical Disease Diabetes Obesity Pancreatic Cancer Endocrine System Thyroid Peptide Hormones Endocrinology Treatment Of Diabetes Neuroendocrine Tumors Acromegaly Hyperparathyroidism Parathyroid Hormone Thyroid Eye Disease Autosomal Dominant Polycystic Kidney Disease Neuroendocrine Tumor Congenital Adrenal Hyperplasia Neuroendocrinology Somatostatin Treatment Of Autosomal Dominant Polycystic Kidney Disease Carcinoid Syndrome Endocrine Related Tumors Graves' Disease

Home Page: www.crinetics.com

6055 Lusk Boulevard
San Diego, CA 92121
United States
Phone: 858 450 6464


Officers

Name Title
Dr. R. Scott Struthers Ph.D. Founder, President, CEO & Director
Dr. Stephen F. Betz Ph.D. Founder & Chief Scientific Officer
Mr. Marc J. C. Wilson CPA Chief Financial Officer
Mr. Jeff E. Knight Chief Operating Officer
Dr. Alan S. Krasner M.D. Chief Endocrinologist
Gayathri Diwakar Head of Investor Relations
Ms. Garlan Adams General Counsel & Corporate Secretary
Ms. Adriana Cabre M.B.A. Chief Human Resources Officer
Mr. Kevin Capps Head of Intellectual Property
Mr. Chris Robillard M.B.A. Chief Business Officer

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 6.4228
Price-to-Sales TTM: 4898.3955
IPO Date:
Fiscal Year End: December
Full Time Employees: 290
Back to stocks